Andreas Tietmann

Intelligent Venture Capital Management GmbH (IVCM) is an independent venture capital firm established in 1999. IVCM is based in Aachen with a representative office in Cologne, both cities in Nordrhein-Westfalen near the western border of Germany. The firm manages the IVC series of funds for a private clientele. The IVC funds are operated as pledge funds, through which private individuals such as entrepreneurs invest in the form of private placements. IVCM also manages the regional seed fund Rheinland Venture Capital, in which the lead investors are regional financial institutions including savings banks. The firm has strategic alliances with government-controlled banks and with High-Tech Gründerfonds Management GmbH, a public-private partnership based in Bonn and specialized in venture capital investing in technology.

Enerparc AG engages in the development, construction, and operation of large-scale photovoltaic systems. It offers engineering, procurement, and construction services. The firm also provides consulting services in all phases of the project, including monitoring and coordinating. The company was founded in November 2008 and is headquartered in Hamburg, Germany.

Deutsche Verrechnungsstelle AG engages in the financing and invoicing business. It also specializes in the schematized sending of reminders to debtors for unpaid bills. In addition, the firm operates as a factoring institution. The company was founded by Sven Ries and Jan Pieper in January 2004 and is headquartered in Cologne, Germany.

W. D. Huth GmbH & Co. KG is a German company that manufactures mining machinery, bearings, and gears. The private company is based in Gevelsberg, Germany. The CEO of the company is Andreas Tietmann.

AplaGen was founded in April 2001 by Prof. Dr. med. Hans-Georg Frank, Prof. Dr. med. Peter Kaufmann and Dr. Franzpeter Bracht. Its basic technologies were a spin-off of the University of Technology Aachen, Germany (RWTH). From this starting point, AplaGen has transformed into a company with broad expertise in peptide design, synthesis and analysis. It has successfully developed own products with independent patent protection for major markets, including the anemia market (EPO-market) and the thrombocytopenia market. The discovery of cytokine-mimetic peptides defines its core expertise. With its proprietary cytokine-mimetic peptide products, AplaGen is approaching large existing biopharmaceutical markets in a 'smart-follower' position, which provides an optimal risk/chance profile. Pharmacokinetic optimization of peptides is based on the approved drug Hydroxyethylstarch (HES) and protected by AplaGen´s IP. As privately held company, AplaGen has closed seed financing in 2001 and a series financing in 2005. AplaGen is dedicated to improvements for patients with dysfunctional bone marrow, especially oncologic patients. Both, erythropoietin and Thrombopoietin mimetic peptides will be developed by AplaGen at least until Phase II. To support this focus on oncologic indications AplaGen is seeking early partners for the erythropoietin mimetic peptide in the indication of renal anemia.

Bryholm Kunststofftechnik GmbH & Co. KG is a German company that manufactures plastic packaging. The private company is based in Stolberg, Germany. The CEO of the company is Andreas Tietmann.